+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Tay-Sachs Disease Treatment Global Market Report 2025 - Product Thumbnail Image

Tay-Sachs Disease Treatment Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Phenylketonuria (PKU) Global Market Report 2025 - Product Thumbnail Image

Phenylketonuria (PKU) Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Metabolic Syndrome Global Market Report 2025 - Product Thumbnail Image

Metabolic Syndrome Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
From
GM1 Gangliosidosis Global Market Report 2025 - Product Thumbnail Image

GM1 Gangliosidosis Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Diabetic Ketoacidosis (DKA) Global Market Report 2025 - Product Thumbnail Image

Diabetic Ketoacidosis (DKA) Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Addison's Disease Global Market Report 2025 - Product Thumbnail Image

Addison's Disease Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
From
Hypoparathyroidism Treatment - Global Strategic Business Report - Product Thumbnail Image

Hypoparathyroidism Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 369 Pages
  • Global
From
Phenylketonuria Treatment - Global Strategic Business Report - Product Thumbnail Image

Phenylketonuria Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 184 Pages
  • Global
From
Hyperphosphatemia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hyperphosphatemia Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 390 Pages
  • Global
From
Acromegaly Treatment - Global Strategic Business Report - Product Thumbnail Image

Acromegaly Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 297 Pages
  • Global
From
From
Liraglutide and Semaglutide - Global Strategic Business Report - Product Thumbnail Image

Liraglutide and Semaglutide - Global Strategic Business Report

  • Report
  • November 2025
  • 451 Pages
  • Global
From
Diabetic Ulcers Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Ulcers Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 384 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 273 Pages
  • Global
From
DPP-IV Inhibitors - Global Strategic Business Report - Product Thumbnail Image

DPP-IV Inhibitors - Global Strategic Business Report

  • Report
  • November 2025
  • 262 Pages
  • Global
From
Fabry Disease Treatment - Global Strategic Business Report - Product Thumbnail Image

Fabry Disease Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 367 Pages
  • Global
From
Insulin Injection Aids - Global Strategic Business Report - Product Thumbnail Image

Insulin Injection Aids - Global Strategic Business Report

  • Report
  • November 2025
  • 280 Pages
  • Global
From
Trulicity - Global Strategic Business Report - Product Thumbnail Image

Trulicity - Global Strategic Business Report

  • Report
  • November 2025
  • 471 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more